David Shaw’s NanoViricides NNVC Stock Holding History

David Shaw’s Portfolio NNVC Stock Details NNVC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-1,546	Closed	-$36K	–	3658
2015 Q4	$36K	Buy	1,546 +63	+4%	+$1.51K	﹤0.01%	3732
2015 Q3	$35K	Sell	1,483 -970	-40%	-$25.7K	﹤0.01%	3673
2015 Q2	$85K	Sell	2,453 -313	-11%	-$11.9K	﹤0.01%	3663
2015 Q1	$124K	Buy	2,766 +1,416	+105%	+$75.5K	﹤0.01%	3506
2014 Q4	$73K	Buy	+1,350	New	+$89.4K	﹤0.01%	3923
2014 Q3	–	Sell	-523	Closed	-$44K	–	4295
2014 Q2	$44K	Buy	+523	New	+$37.1K	﹤0.01%	4111

Other funds holding NNVC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

David Shaw's NNVC Position: Q1 2016 in Review

David Shaw sold out of NanoViricides (NNVC) in Q1 2016, closing a stake of 1,546 shares — an estimated $36K sold.

David Shaw first reported a position in NNVC in Q2 2014 and held it in 6 quarters. The position peaked at $124K in Q1 2015. 55 funds tracked by Wall St. Rank hold NNVC as of Q1 2016.

David Shaw reported no remaining NanoViricides position as of Q1 2016 after selling out during the quarter.
David Shaw sold 1,546 NanoViricides shares in Q1 2016, an estimated $36K.
David Shaw first reported a position in NanoViricides in Q2 2014 and held it in 6 quarters.
David Shaw's NanoViricides position peaked at $124K in Q1 2015.
55 funds tracked by Wall St. Rank held NanoViricides as of Q1 2016.

Based on D.E. Shaw & Co's 13F filing for Q1 2016, filed 16 May 2016.